Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225809 | 0.66 | KMT2A (0.50) | ALDH1A1MAPTCA1CA2CA4 | |
| SCHEMBL7549489 | 0.64 | — | — | |
| SCHEMBL632498 | 0.63 | CA1 (0.33) | CA1CA2CA4KMT2A | |
| SCHEMBL28122971 | 0.61 | ALDH1A1 (0.38) | ALDH1A1MAPTL3MBTL1CA1CA2 | |
| SCHEMBL7825990 | 0.61 | CA1 (0.32) | CA1CA2CA4KMT2A | |
| SCHEMBL12475098 | 0.60 | L3MBTL1 (0.41) | ALDH1A1MAPTL3MBTL1CA1CA2 | |
| SCHEMBL5336897 | 0.60 | CA1 (0.40) | ALDH1A1MAPTCA1CA2CA4 | |
| SCHEMBL382537 | 0.59 | HPD (0.36) | ALDH1A1MAPTL3MBTL1CA1CA2 | |
| SCHEMBL170644 | 0.58 | CA1 (0.39) | ALDH1A1MAPTL3MBTL1CA1CA2 | |
| SCHEMBL26828454 | 0.58 | CA1 (0.50) | ALDH1A1MAPTCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228601-A1 | BIOCOMPATIBLE CROSSLINKED HYDROGELS, DRUG-LOADED HYDROGELS AND METHODS OF USING THE SAME | SURGICAL SPECIALTIES CORPORATION LIMITED (GB) | 2016-08-11 | — | — | US | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-9125814-B2 | Biocompatible crosslinked hydrogels, drug-loaded hydrogels and methods of using the same | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2015-09-08 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-8617584-B2 | Adhesive tissue repair patch and collagen sheets | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-12-31 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8460708-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-06-11 | — | — | US | disclosed |
| WO-2002102864-A1 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | COHESION TECHNOLOGIES, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-6495127-B1 | INTERPENETRATING POLYMER NETWORKS | COHESION TECHNOLOGIES, INC. | 2002-12-17 | — | — | US | disclosed |
| US-6482179-B1 | Apparatuses, methods and compositions for closing tissue puncture openings | COHESION TECHNOLOGIES, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020165337-A1 | Rapid-gelling biocompatible polymer composition and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2002-11-07 | — | — | US | disclosed |
| US-6458889-B1 | CROSSLINKING NUCLEOPHILIC AND ELECTROPHILIC MATERIAL; BONDING STRENGTH | COHESION TECHNOLOGIES, INC. | 2002-10-01 | — | — | US | disclosed |
| EP-1218437-A1 | COMPOSITIONS THAT FORM INTERPENETRATING POLYMER NETWORKS FOR USE AS HIGH STRENGTH MEDICAL SEALANTS | Cohesion Technologies, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020042473-A1 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2002-04-11 | — | — | US | disclosed |
| US-20010055615-A1 | SULFHYDRYL GROUP REACTIVE WITH GROUPS AND POLYOXYALKYLENE OXIDE | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2001-12-27 | — | — | US | disclosed |
| US-6312725-B1 | SULFHYDRYL GROUP REACTIVE WITH GROUPS AND POLYOXYALKYLENE OXIDE | COHESION TECHNOLOGIES, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001016210-A1 | COMPOSITIONS THAT FORM INTERPENETRATING POLYMER NETWORKS FOR USE AS HIGH STRENGTH MEDICAL SEALANTS | COHESION TECHNOLOGIES, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228601-A1 | BIOCOMPATIBLE CROSSLINKED HYDROGELS, DRUG-LOADED HYDROGELS AND METHODS OF USING THE SAME | PTGES, PTGS1, HPGDS | ALDH1A1 168/4885MAPT 4006/4885L3MBTL1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.